Navigation Links
MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Date:3/13/2008

p>

-------------------------------------------------------------------------

-------------------------------------------------------------------------

STATEMENTS OF CASH FLOWS

Unaudited - In Thousands

of Canadian dollars

Loss for the period $(3,424) $(6,726) $(9,521) $(12,924)

Items not affecting cash:

Amortization 173 234 427 693

Write-down of intangible

assets 474 3,316 474 3,316

Stock-based compensation 51 47 236 282

Issuance of deferred

share units - - - 96

Accretion of convertible

royalty participation

units and amortization

of transaction costs 485 389 1,331 1,108

Changes in non-cash

working capital items

relating to operating

activities (207) 564 54 (112)

-------------------------------------------------------------------------

Cash used in operating

activities $(2,448) $(2,176) $(6,999) $(7,541)

-------------------------------------------------------------------------

Issuance of convertible

royalty participation

units - - - 7,732

Issuance of common shares,

net of issue costs - 10,133 - 10,133

Proceeds on exercise of

stock options - - - 10

Proceeds on exercise of

warrants - 17 36 172

Repayment of capital lease

obligation - - - (5)

---------------------------------------------------------
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX releases CEO message #22
3. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
4. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
8. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
9. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... September 19, 2014 BioTech News ... patents and results of studies and trials.  Companies in ... Company (NYSE: LLY ), Gilead Sciences Inc. ... CELG ) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) ... developing prodrug therapeutics for the treatment of cancer, announced ...
(Date:9/19/2014)... ROCKLAND, Massachusetts , September 19, 2014 ... with the 53rd European Society for Paediatric Endocrinology (ESPE) ... advancement of science and medical research in the field ... of Merck KGaA, Darmstadt, Germany , ... Growth Innovation (GGI) for 2014. The awards were announced ...
(Date:9/18/2014)... 2014 About POCT ... a clinical laboratory. It helps in making fast ... and medication. POCT is gaining popularity due to ... such as diabetes, heart disease, and obesity. It ... standardized to minimize errors during the diagnosis of ...
(Date:9/18/2014)... , September 18, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced ... Materials - Global Strategic Business Report" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the ... US$ Million by the following Product ...
Breaking Biology Technology:Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3
... have found a defense against the Black Plague, a disease ... Middle Ages and which government agencies perceive as a terrorist ... team have developed a vaccine that early research shows is ... of Health and USDA funded research appear in the August ...
... COLLEGE STATION, Sept. 24, 2008 America,s war on ... agents, and Texas A&M University chemist Dr. Frank Raushel ... that might neutralize one such chemical agent, the organophosphates. ... the 1930s but soon made their way into the ...
... (Nasdaq: SVNT ) today announced that Christopher,Clement, President ... corporate update at the upcoming Lazard Capital Markets 5th,Annual ... on Tuesday, November 18, 2008 at,9:25 a.m. ET. The ... in New,York City November 18-19, 2008., Individuals can ...
Cached Biology Technology:UCF professor develops vaccine to protect against black plague bioterror attack 2UCF professor develops vaccine to protect against black plague bioterror attack 3Researcher working on destruction of chemical weapons 2Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th 2
(Date:9/21/2014)... are set to rise again in 2014 - reaching a ... cent projected rise in burning fossil fuels is revealed by ... by researchers at the Tyndall Centre for Climate Change Research ... Engineering, Mathematics and Physical Sciences at the University of Exeter. ... where world leaders will seek to catalyse action on climate ...
(Date:9/21/2014)... strains of bacteria have emerged that resist even the ... forms of tuberculosis and staphylococcus, infect more than 2 ... the urgent need for new treatments, scientists have discovered ... decade. , MIT engineers have now turned a powerful ... that can disable any target gene, they have shown ...
(Date:9/21/2014)... mussels and barnacles secrete very sticky proteins that help ... Inspired by these natural adhesives, a team of MIT ... to repair ships or help heal wounds and surgical ... MIT researchers engineered bacteria to produce a hybrid material ... a bacterial protein found in biofilms slimy layers ...
Breaking Biology News(10 mins):CO2 emissions set to reach new 40 billion ton record high in 2014 2CO2 emissions set to reach new 40 billion ton record high in 2014 3Battling superbugs 2Battling superbugs 3Battling superbugs 4Engineered proteins stick like glue -- even in water 2Engineered proteins stick like glue -- even in water 3
... The involvement of locals is a key ingredient in ... fish stocks. The largest-scale study to date of how ... that human population pressure was a critical factor in whether ... but so too was local involvement in research and management. ...
... title of an upcoming symposium at the American Association for ... California. And it,s a topic that should not be taken ... in the department of geography at the University of British ... to climate change due to higher ocean temperatures. ...
... a cardiac arrhythmia a chronic irregularity of heartbeat ... Germany. Although the condition is not acutely life-threatening, it ... such as cardiac insufficiency, stroke and dementia. In the ... international team of researchers, led by LMU physician PD ...
Cached Biology News:Participaton 'important for healthy marine parks' 2Will coral reefs disappear? 2When the heart gets out of step 2When the heart gets out of step 3
Rabbit Anti-Human Janus Kinase 2 (JAK2 Polyclonal Antibody Family: Protein Kinase Sub-Family: TYK2/JAK Applications: ELISA, Western Blot...
Goat polyclonal to Lipocalin 2...
Human GCP-2 is a member of the CXC family of chemokines. It also promotes neutrophil chemotaxis and deganulation. GF063 is an 8.0 kDa protein containing 73 amino acid residues....
... immunoblotting the antibody reacts against the reduced ... MMP-2 or MMP-2 bound to TIMP-2. affinity ... Solution in 0.01 M phosphate buffered ... 15 mM sodium azide. synthetic peptide corresponding ...
Biology Products: